


FDA Update about Bacterial Contamination of Platelets

December 8, 2021



The United States Food and Drug Administration (FDA) issued guidance to reduce the risk of septic transfusion reactions associated with platelets. One of the approved mitigation strategies is pathogen reduction. The FDA issued a new bulletin that there have been three reported cases of septic transfusion reactions in the United States since 2019 from bacterial contamination of platelets. Two of three of these cases were fatal. All three were contaminated with either *Acinetobacter* spp, *Staphylococcus saprophyticus*, *Leclercia adecaoboxylata*, or combinations of these species despite these units being pathogen reduced. Since 2018, seven cases of platelet septic transfusion reactions have been reported. Based on genetic testing by the U.S. Centers for Disease Control and Prevention (CDC) all of these cases may have a common, unidentified source. The U.S. CDC and FDA will continue to monitor the situation and ask blood establishments and transfusion services to be alert and report any additional cases of potential septic transfusion reactions.

Reference:


[U.S. Food & Drug, Safety and Availability \(Biologics\) Bulletin. Important information for blood establishments and transfusion services regarding bacterial contamination of platelets for transfusion.](#)



Filed Under

- Coagulation & Plasma Transfusion
- News

Recommended



Lower Transfusion Thresholds do not Harm Septic Shock Patients



FDA Reports Safest Blood Supply in History




Patients with Moderate ADAMTS13 Deficiency have Increased Risk of Dying

[Show Comments](#)

[Get the latest news. Subscribe to our mailing list.](#) [SIGN UP](#)

Latest News

FROM OUR SPONSOR



Join us to learn the basics in RHD genetics and biochemistry



Outpatient COVID-19 Convalescent Plasma Reduces Hospitalizations



Cold-Stored Group O Whole Blood Use in Severely Injured Patients



FDA Update about Bacterial Contamination of Platelets



Daprodustat is Noninferior to Erythropoiesis-Stimulating Agents for Patients with Chronic Kidney Disease Undergoing Dialysis

[LOAD MORE NEWS](#)

WEBINAR

Transfusion Science Webinar

Dive into the "D" discrepancies!

BIO RAD

Recent Tweets

- [AABB](#) 14h
Early outpatient CCP use may reduce hospitalization risk by 54% compared to placebo, according to pre-print findings from @HopkinsMedicine and @JohnsHopkinsSPH. <https://bit.ly/3egH4JX>
Image for the Tweet beginning: Early outpatient CCP use may
- [AABB](#) 14h
Follow us on Twitter @TransfusionNews

Answer the Question of the Day
[Transfusion News](#)